Overview

Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients With Unresectable Pancreatic Cancer.

Status:
Active, not recruiting

Trial end date:
2035-03-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the recommended dose of TBI-1401(HF10) treatment in combination with chemotherapy (Gemcitabine + Nab-paclitaxel or TS-1) in patients with stage III or IV unresectable pancreatic cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Takara Bio Inc.

Collaborator:

Otsuka Pharmaceutical Co., Ltd.

Treatments:

Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel
Tegafur